Syngene

Bengaluru, India Founded: 1993 • Age: 33 yrs Listed
Provider of contract research and manufacturing services for both small molecules and biologics
Request Access
Report Incorrect Data
Page last updated

About Syngene

Syngene is a publicly listed company based in Bengaluru (India) founded in 1993. It operates as a provider of contract research and manufacturing services for both small molecules and biologics. Syngene has raised $85.89 million across 3 funding rounds from investors including Goldman Sachs, Morgan Stanley and GE Capital. The company has 8,230 employees. Syngene has completed 1 acquisition, including Strand Life Sciences. Its chief executive is Jonathan Hunt. Its website syngeneintl.com draws about 94 thousand monthly visits. Its Indian entity Syngene International Limited reported revenue of ₹3,491 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Diversified. Its competitors include Abzena, Patheon, Piramal Group, Maravai Life Sciences and LakePharma and 3 more; 4 of its 8 listed competitors have raised funding.

Company details

Syngene was founded in 1993 in Bengaluru, India, as a provider of contract research and manufacturing in the biotechnology sector. Discovery services are extended across small molecules, large molecules, antibody-drug conjugates, and oligonucleotides. Biological operations encompass recombinant DNA engineering, cell line development, protein sciences, assay biology, DMPK, in vivo pharmacology, and toxicology. Synthetic and medicinal chemistry support is integrated with biological and DMPK elements for comprehensive solutions.

Recognitions & Rankings of Syngene

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#184
Valuation
₹21,972 Cr
  • Headquarters Bengaluru, India
  • Employees 8,230
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website syngeneintl.com
  • Social LinkedIn X
  • Legal Name Syngene International Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹16,046 Cr

    SYNGENE · NSE

  • Share Price
    ₹385.95

    -2.91% today

  • Revenue
    ₹3,739 Cr

    FY 2025-26 · +2.6% YoY

  • EBITDA
    ₹842 Cr

    Margin 22.5%

  • Net Profit
    ₹372 Cr

    FY 2025-26 · -15.8% YoY

  • P/E (TTM)
    52.6x

    P/B 3.2x

  • ROE
    7.8%

    ROCE 9.5%

  • Debt / Equity
    0.11

    Interest cover 12.5x

  • Total Equity Funding
    $85.89M (USD)

    in 3 rounds

  • Latest Funding Round
    $131.23M (USD), Post-IPO

    Feb 2023

  • Investors
    Goldman Sachs

    & 7 more

  • Employee Count
    8,230
  • Investments & Acquisitions
    Strand Life Sciences

Funding Insights of Syngene

Syngene has successfully raised a total of $85.89M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $131.23 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $85.89M
  • Total Rounds 3
  • Last Round Post-IPO — $131.23M
  • First Round $23.24M

    (Oct 2012)

  • Investors Count 8

All 3 funding rounds of Syngene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2023$131.23MPost-IPO––
GIC, MAS
Sep 2014$62.65MPrivate Equity Round–True North
–
Oct 2012$23.24MPrivate Equity Round––
GE Capital
Valuation history

8 investors in total: 8 institutional.

Investors in Syngene

Syngene has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Morgan Stanley and GE Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
GIC
Sovereign wealth is managed and private equity investments are facilitated.
–gic.com.sgSingapore, Singapore
Goldman Sachs
Investment banking services are delivered across multiple financial sectors.
1869goldmansachs.comNew York, United States
Caisse de depot et placement du Quebec
Investment strategies are provided across diverse asset classes and markets.
1965cdpq.comQuebec City, Canada
True North
Private equity is invested by True North in mid-market companies.
–truenorth.co.inMumbai, India
Monetary Authority of Singapore
Central bank
–mas.gov.sgSingapore, Singapore
Morgan Stanley
Wealth management, investment advisory, and financial services are provided.
1935morganstanley.comNew York, United States
Abu Dhabi Investment Authority
Long-term value is created through diversified sovereign wealth investments.
–adia.aeAbu Dhabi, United Arab Emirates
GE Capital
Commercial aircraft and equipment leasing and lending services are provided.
1932gecapital.comUnited States
Premium access

Investor details for Syngene

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Syngene International Limited (Syngene)

Syngene International Limited is the primary company behind Syngene. The board of Syngene International Limited currently have 11 directors; the longest-serving is Kiran Mazumdar Shaw, appointed in 1993. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Kiran Mazumdar Shaw
DIN 00347229
Whole-time director18 Nov 199332 yrs 11 moSyngene International Limited
Catherine Patricia Rosenberg
DIN 06422834
Director08 Aug 200026 yrs 2 moSyngene International Limited
Vinita Bali
DIN 00032940
Director31 Jul 20179 yrs 2 moSyngene International Limited
Sharmila Abhay Karve
DIN 05018751
Director01 Aug 20197 yrs 2 moSyngene International Limited
Nilanjan Roy
DIN 02703775
Director01 Apr 20242 yrs 6 moSyngene International Limited
Manja Hermina Maria Boerman Elisabeth
DIN 10655368
Director04 Jun 20242 yrs 4 moSyngene International Limited
Sanjaya Singh
DIN 11122562
Director01 Jul 20251 yr 3 moSyngene International Limited
Suresh Narayanan
DIN 07246738
Director01 Aug 20251 yr 2 moSyngene International Limited
Siddharth Mittal
DIN 03230757
Managing Director01 Jul 20263 moSyngene International Limited
Vijaya Chandru
DIN 00914988
Director29 Jul 20262 moSyngene International Limited
Arun Suresh Chandavarkar
DIN 01596180
Director29 Jul 20262 moSyngene International Limited

People of Syngene

76 people are tracked at Syngene (32 in leadership, 8 in board & advisors, 36 in team); the tracked headcount is 8,230.

NameRoleGroup
Jonathan Hunt
CEOLeadership
Vibhuti Mishra
Associate General Manager - Business Development & Head Of PresalesLeadership
Peter Bains
CEO DesignateLeadership
Purushottam Singnurkar
Head of Formulations DevelopmentLeadership
Tj Jung
Senior Director Business DevelopmentLeadership
Vivek Sah
Chief Marketing OfficerLeadership
Shilpi Priyadarshini
Director Discovery Sales, North America - East CoastLeadership
Kevin Barnett
Executive Director Of Business DevelopmentLeadership
David Siebert
Director Of Business Development, Discovery Services, Germany & AustriaLeadership
Rajkumar Agarwal
Vice President - Business Development - Clinical DevelopmentLeadership
Jeremiah Treanor
Director Of Business DevelopmentLeadership
Nan Zhao
Director Of Business Development, Discovery ServicesLeadership
Caroline Hempstead
(Interim) Chief Commercial OfficerLeadership
Davina Heller
Sr. Director Business DevelopmentLeadership
Kaushik Bhattacharya
Assistant General Manager - Business Development (global)Leadership
Manoj Babu
Vice President, Business DevelopmentLeadership
Bill Lidster
Executive Director Business DevelopmentLeadership
Lucia Babes
Vice President Of Sales - Discovery ServicesLeadership
Kaustubh H Ronghe
General Manager - EngineeringLeadership
Manish Jabshetti
Deputy General Manager Operations And Tech TransferLeadership

56 more people are available in the full profile.

Premium access

Complete people profiles for Syngene

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Syngene

Syngene is a publicly listed company on the NSE with ticker symbol SYNGENE in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date11 Aug 2015
  • Listed onNSE: SYNGENE · BSE: 539268
  • Listed entitySyngene International Ltd.
  • Exchange sectorCommercial services
  • ISININE398R01022
  • Share price₹391.15 (+3.06% on the day) · 2026-10-14
  • Market capitalisation₹15,305 Cr
  • Price to earnings71.2
  • EPS (diluted, trailing year)₹5.49
  • Dividend yield0.34%
  • Volume (last session)636,909

Financials of Syngene

Exchange-reported figures of Syngene International Limited, the listed company behind Syngene (NSE: SYNGENE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,739 Cr
+2.6% YoY
EBITDA
₹842 Cr
-19.2% YoY
Profit After Tax
₹372 Cr
-15.8% YoY
Net Worth
₹4,839 Cr
+2.4% YoY
Total Assets
₹5,562 Cr
-0.1% YoY
Total Debt
₹458 Cr
-20.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,7393,6423,4893,1932,6042,1842,012
Revenue growth+2.6%+4.4%+9.3%+22.6%+19.2%+8.6%-
EBITDA8421,0421,003934711672618
EBITDA margin+22.5%+28.6%+28.8%+29.3%+27.3%+30.8%+30.7%
Profit before tax411660621594484469517
Net profit372442521470418380358
Net profit margin+10.0%+12.1%+14.9%+14.7%+16.0%+17.4%+17.8%
EPS (₹)7.8612.3312.6911.579.8810.1210.30
Balance sheet
Total assets5,5625,5695,0974,7554,6154,0263,315
Net worth4,8394,7274,2583,6183,2982,8212,176
Total debt4585785558151,022893773
Cash & bank833787564532518643282
Net working capital19444939252549352626.70
Cash flow
Cash from operations9151,1681,042824581701677
Cash from investing(839)(744)(494)(653)(611)(629)(424)
Cash from financing(215)(142)(551)(342)(31.30)58.00(226)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7361,0369179118741,018944891
Revenue growth (YoY)-15.8%+1.8%-2.8%+2.2%+10.7%---
Other income25.3022.2015.4015.4017.7018.9018.3016.50
EBITDA77.30297139200206344284245
EBITDA margin+10.5%+28.7%+15.1%+21.9%+23.6%+33.8%+30.1%+27.5%
Depreciation112112114116111106109111
Interest9.6012.1011.9013.2011.6015.9012.4013.10
Profit before tax(19.20)19628.4085.20101240181137
Tax(10.20)48.1013.4018.1014.6057.2049.7031.20
Net profit(9.00)14815.0067.1086.70183131106
EPS (₹)(0.22)3.670.371.672.164.563.262.64
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,4243,3733,2033,1942,6012,1792,012
Revenue growth+1.5%+5.3%+0.3%+22.8%+19.4%+8.3%-
EBITDA741918868934708670617
EBITDA margin+21.7%+27.2%+27.1%+29.3%+27.2%+30.7%+30.7%
Profit before tax395622557601482467516
Net profit360415467470416379358
Net profit margin+10.5%+12.3%+14.6%+14.7%+16.0%+17.4%+17.8%
EPS (₹)7.5711.6311.6011.789.8310.0910.29
Balance sheet
Total assets5,1695,2064,8064,5774,6094,0223,314
Net worth4,7044,6394,1923,6193,2922,8182,174
Total debt2013063326391,022893773
Cash & bank724652528509515638280
Net working capital37.9023533178948852324.70
Cash flow
Cash from operations8311,114913838582698677
Cash from investing(766)(810)(383)(685)(611)(629)(424)
Cash from financing(178)(136)(536)(340)(31.30)58.00(226)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue663960834830799948877821
Revenue growth (YoY)-17.1%+1.2%-4.9%+1.1%+10.0%---
Other income24.8021.6014.5014.2016.6018.4018.0016.40
Total expenses598683716653631638626613
EBITDA64.90277119178168310251209
EBITDA margin+9.8%+28.8%+14.2%+21.4%+21.0%+32.7%+28.6%+25.4%
Depreciation95.6095.3097.1010094.6089.6092.3093.70
Interest4.106.506.207.405.9010.106.707.00
Profit before tax(10.00)19730.1084.2084.20229170124
Tax(7.90)48.5013.6018.0010.2054.3046.7027.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7361,0369179118741,018944891
Revenue growth (YoY)-15.8%+1.8%-2.8%+2.2%+10.7%---
Other income25.3022.2015.4015.4017.7018.9018.3016.50
EBITDA77.30297139200206344284245
EBITDA margin+10.5%+28.7%+15.1%+21.9%+23.6%+33.8%+30.1%+27.5%
Depreciation112112114116111106109111
Interest9.6012.1011.9013.2011.6015.9012.4013.10
Profit before tax(19.20)19628.4085.20101240181137
Tax(10.20)48.1013.4018.1014.6057.2049.7031.20
Net profit(9.00)14815.0067.1086.70183131106
EPS (₹)(0.22)3.670.371.672.164.563.262.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,7393,6423,4893,1932,6042,1842,012
Revenue growth+2.6%+4.4%+9.3%+22.6%+19.2%+8.6%-
Other income70.7010490.6070.9010899.60153
Total expenses2,8972,6012,4852,2581,8941,5121,394
Employee cost1,105984889842718660580
EBITDA8421,0421,003934711672618
EBITDA margin+22.5%+28.6%+28.8%+29.3%+27.3%+30.8%+30.7%
Depreciation453433426366310274219
Interest48.8053.1047.2045.2024.1027.7034.60
Profit before tax411660621594484469517
Tax94.2016411112988.6064.30105
Net profit372442521470418380358
Net profit margin+10.0%+12.1%+14.9%+14.7%+16.0%+17.4%+17.8%
EPS (₹)7.8612.3312.6911.579.8810.1210.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital403402402401401400400
Reserves & surplus4,4364,3243,8563,2172,8972,4211,776
Shareholders' funds (net worth)4,8394,7274,2583,6183,2982,8212,176
Minority interest0.000.000.000.000.000.000.00
Secured loans9.40102142575532512377
Unsecured loans449475414240490380396
Total debt4585785558151,022893773
Total liabilities5,5625,5695,0974,7554,6154,0263,315
Assets
Gross block5,9025,3075,0244,5473,9443,4603,017
Net block3,0002,8022,8502,6672,3932,2012,020
Capital work in progress1,0461,266838177346237234
Investments7416475489181,034702776
Inventories14115623833317959.6025.20
Sundry debtors509527442529508476398
Cash & bank balances833787564532518643282
Loans & advances204208202207237206169
Total current assets1,6871,6771,4461,6011,4421,383874
Total current liabilities1,4921,2271,0541,076949858848
Net working capital19444939252549352626.70
Total assets5,5625,5695,0974,7554,6154,0263,315
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash36785.7089.50262323193165
Net cash from operating activities9151,1681,042824581701677
Net cash from investing activities(839)(744)(494)(653)(611)(629)(424)
Net cash from financing activities(215)(142)(551)(342)(31.30)58.00(226)
Net change in cash(138)281(3.80)(172)(61.50)13027.80
Closing cash833787564532518643282
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.6%+4.4%+9.3%+22.6%+19.2%+8.6%-
EBITDA growth-19.2%+3.8%+7.4%+31.5%+5.8%+8.7%-
PBT growth-37.7%+6.3%+4.6%+22.5%+3.2%-9.2%+24.4%
Net income growth-15.8%-15.2%+10.7%+12.6%+10.0%+5.9%-
Revenue CAGR (3Y)+5.4%+11.8%+16.9%+16.6%+12.6%+15.4%-
EBITDA CAGR (3Y)-3.4%+13.6%+14.3%+14.8%+9.8%+13.1%-
Profitability & leverage
Net income margin+8.5%+13.6%+14.6%+14.5%+15.2%+18.5%+20.5%
Return on capital employed+9.5%+13.4%+13.6%+13.6%+11.8%+13.5%+15.1%
Return on net worth+7.8%+11.1%+13.0%+13.4%+12.9%+16.2%+17.3%
Debt / equity0.110.130.170.270.310.330.38
Long-term debt / equity0.080.100.150.210.220.140.11
Interest cover12.548.728.177.966.016.978.68
Efficiency & per share
Fixed asset turnover0.670.710.730.750.700.670.78
Inventory turnover25.1918.4912.2112.4721.7951.5258.66
Debtors turnover7.227.527.196.166.155.005.46
EPS (₹)7.8612.3312.6911.579.8810.1210.30
Dividend per share (₹)1.251.251.251.251.000.000.00
Book value per share (₹)120.11117.44105.9190.1382.2870.5454.40
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue663960834830799948877821
Revenue growth (YoY)-17.1%+1.2%-4.9%+1.1%+10.0%---
Other income24.8021.6014.5014.2016.6018.4018.0016.40
Total expenses598683716653631638626613
EBITDA64.90277119178168310251209
EBITDA margin+9.8%+28.8%+14.2%+21.4%+21.0%+32.7%+28.6%+25.4%
Depreciation95.6095.3097.1010094.6089.6092.3093.70
Interest4.106.506.207.405.9010.106.707.00
Profit before tax(10.00)19730.1084.2084.20229170124
Tax(7.90)48.5013.6018.0010.2054.3046.7027.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,4243,3733,2033,1942,6012,1792,012
Revenue growth+1.5%+5.3%+0.3%+22.8%+19.4%+8.3%-
Other income66.9010288.0070.9010899.60153
Total expenses2,6822,4562,3352,2591,8941,5091,395
Employee cost904842761812698642572
EBITDA741918868934708670617
EBITDA margin+21.7%+27.2%+27.1%+29.3%+27.2%+30.7%+30.7%
Depreciation387367369359310274219
Interest26.0031.2029.5045.2024.1027.7034.60
Profit before tax395622557601482467516
Tax90.3015490.8012887.9063.70104
Net profit360415467470416379358
Net profit margin+10.5%+12.3%+14.6%+14.7%+16.0%+17.4%+17.8%
EPS (₹)7.5711.6311.6011.789.8310.0910.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital403402402401401400400
Reserves & surplus4,3014,2363,7903,2182,8912,4181,774
Shareholders' funds (net worth)4,7044,6394,1923,6193,2922,8182,174
Secured loans0.00102142575532512377
Unsecured loans20120419163.30490380396
Total debt2013063326391,022893773
Total liabilities5,1695,2064,8064,5774,6094,0223,314
Assets
Gross block5,1384,5614,3714,0713,9443,4603,017
Net block2,4872,2412,3182,2602,3932,2012,020
Capital work in progress541880760126346237234
Investments1,5641,4689289411,034702777
Inventories13715023433317959.6025.20
Sundry debtors432469428484508339398
Cash & bank balances724652528509515638280
Loans & advances138164170733237341169
Total current assets1,4321,4361,3592,0601,4401,378873
Total current liabilities1,3941,2011,0281,271952855848
Net working capital37.9023533178948852324.70
Total assets5,1695,2064,8064,5774,6094,0223,314
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash23466.6072.10259319192164
Net cash from operating activities8311,114913838582698677
Net cash from investing activities(766)(810)(383)(685)(611)(629)(424)
Net cash from financing activities(178)(136)(536)(340)(31.30)58.00(226)
Net change in cash(113)167(5.50)(187)(59.90)12728.10
Closing cash724652528509515638280
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.5%+5.3%+0.3%+22.8%+19.4%+8.3%-
EBITDA growth-19.2%+5.8%-7.1%+32.0%+5.7%+8.6%-
PBT growth-36.4%+11.5%-7.3%+24.8%+3.1%-9.4%+24.5%
Net income growth-13.1%-11.2%-0.8%+13.2%+9.8%+5.8%-
Revenue CAGR (3Y)+2.4%+9.1%+13.7%+16.7%+12.5%+15.3%+18.8%
EBITDA CAGR (3Y)-7.4%+9.0%+9.0%+14.9%+9.7%+13.0%+17.0%
Profitability & leverage
Net income margin+8.9%+13.9%+14.6%+14.8%+15.1%+18.5%+20.5%
Return on capital employed+9.4%+13.0%+12.5%+14.1%+11.7%+13.5%+15.0%
Return on net worth+7.7%+10.6%+12.0%+13.7%+12.9%+16.2%+17.3%
Debt / equity0.050.070.120.240.310.330.38
Long-term debt / equity0.040.050.100.190.220.140.11
Interest cover7.345.675.917.866.057.008.71
Efficiency & per share
Fixed asset turnover0.710.760.760.800.700.670.78
Inventory turnover23.8417.5611.3012.4721.7751.4058.66
Debtors turnover7.597.527.036.436.145.915.46
EPS (₹)7.5711.6311.6011.789.8310.0910.29
Dividend per share (₹)1.251.251.251.251.000.000.00
Book value per share (₹)116.75115.25104.2790.1682.1470.4654.35

Investments & Acquisitions by Syngene

Syngene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Strand Life Sciences.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Strand Life Sciences
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
strandls.comBengaluru, India2000Sep 2016••••
Premium access

Complete acquisition details for Syngene

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Syngene

5 dated milestones of Syngene across 30 years, from founding to its latest funding, stage changes and deals.

  1. Founded Syngene is founded.
  2. Funding First funding round of $23.2M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Strand Life Sciences.
  5. Funding Latest funding round, Post-IPO, of $131.2M.

Competitors of Syngene

Syngene has 8 listed competitors in our database, 4 of them funded. They include Abzena, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Abzena
abzena.com2001Cambridge, United Kingdom$67.11M306
Provider of antibody discovery, cell line development, and bio analytics services
Patheon
patheon.com1974Durham, United States$141M–
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
Piramal Group
piramal.com1984Mumbai, India–204
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
Maravai Life Sciences
maravai.com2014San Diego, United States–650
Provides enabling tools and services in the life sciences research and bio-production industries
LakePharma
lakepharma.com2009Belmont, United States$30M212
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering
Grand River Aseptic Manufacturing
grandriverasepticmfg.com2010Grand Rapids, United States$16.93M293
Sterile parenteral CDMO services for development and manufacturing are offered.
Panacea Biotec
panaceabiotec.com1984Ambala, India–2,095
Developer of biosimilars, vaccines and natural products
Insud Pharma
insudpharma.com1977Madrid, Spain––
Finished formulations, APIs, and monoclonal antibodies are developed and manufactured.
Premium access

Detailed competitors of Syngene

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Syngene

The website of Syngene (syngeneintl.com) receives about 94K visits a month and ranks #525,515 among all websites worldwide, #539 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    94K

    ▲ 57.5% vs previous month

  • Unique visitors
    31.3K

    per month

  • Global rank
    #525,515

    among all websites

  • Category rank
    #539

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Syngene. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
RD-Biotech
rd-biotech.com
100%
1.7K#11,064,917View details
Covance
covance.com
100%
20.2K#688,229View details
paris-biotech.com
paris-biotech.com
100%
–––
fapon.com
fapon.com
100%
–––
Avid Bioservices
avidbio.com
100%
12.3K#1,697,368View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 18 similar websites and full traffic analytics for Syngene

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 18 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

10 companies that operate in the same segment as Syngene (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Evotec
Drug discovery and development services are provided to biopharma sector.
1993Hamburg, Hamburg, GermanyUSD 25 MUSD 926.33 M4,830
Pharmaron
Drug discovery and development services for small molecules are provided.
2003Beijing, ChinaUSD 320 M–476
Indegene
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M4,490
Insulet
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
MannKind Corp
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Pfizer
Pharmaceutical products for treating multiple diseases are provided.
1849New York, New York, United StatesUSD 8 MUSD 266.99 M1,770
LabCorp
Provider of laboratory tests for physicians
1969Burlington, Vermont, United States–USD 13.95 B70,000
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Syngene

Mid-cap stocks: These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts - The Economic Times
Economic Times • 21 days ago
Syngene International: To Hold Meeting With Analysts And Investors On September 24 At Noon
Exchange Update • 1 month ago
Mid-cap stocks: These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts - The Economic Times
Economic Times • 1 month ago
Volumes spurt at Syngene International Ltd counter | Capital Market News - Business Standard
Business Standard • 2 months ago
Kenneth Andrade-backed Old Bridge MF adds Jubilant FoodWorks, Redington, Delhivery; exits Axis Bank, Syngene International
Moneycontrol • 2 months ago
Buy or sell: Gift Nifty signals gap-down start, Vaishali Parekh recommends three intraday stocks to buy today
Mint • 2 months ago
Kiran Mazumdar-Shaw admits Syngene 'lost momentum'. Here's what went wrong
Moneycontrol • 2 months ago
SYNGENE: Q1 revenue fell 16% as CDMO and discovery reposition for growth, with margins set to recover
Quartr • 2 months ago
SYNGENE: Q1 FY27 revenue fell 16% YoY, with margins dropping sharply amid client and forex headwinds
Quartr • 2 months ago
Syngene posts Q1 net loss, flags weak offtake from key biologics client
Moneycontrol • 2 months ago
Premium access

Complete news archive for Syngene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Syngene

Syngene was founded in 1993 and raised its 1st funding round 19 years after it was founded.

Syngene is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Jonathan Hunt is the current CEO of Syngene.

Syngene is a funded company, having raised a total of $85.89M across 3 funding rounds to date. The company's 1st funding round was a Private Equity Round of $23.24M, raised on Oct 2012.

Syngene has 8,230 employees.

The primary company behind Syngene, Syngene International Limited, reported revenue of ₹3,491 Cr for FY 2026, up 3% year on year.

Syngene was founded in 1993 in Bengaluru, India, as a provider of contract research and manufacturing in the biotechnology sector. Discovery services are extended across small molecules, large molecules, antibody-drug conjugates, and oligonucleotides. Biological operations encompass recombinant DNA engineering, cell line development, protein sciences, assay biology, DMPK, in vivo pharmacology, and toxicology. Synthetic and medicinal chemistry support is integrated with biological and DMPK elements for comprehensive solutions.

Syngene's top competitors include Abzena, Grand River Aseptic Manufacturing and Patheon.

Yes, Syngene is publicly traded on NSE under the ticker symbol SYNGENE.

Syngene has made 1 acquisition, including Strand Life Sciences.

Syngene has 8 investors. Key investors include Goldman Sachs, Morgan Stanley, GE Capital, Caisse de depot et placement du Quebec, and GIC.

Syngene operates through Syngene International Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available